Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Qualigen Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of treatments for adult and pediatric cancer in the United States. The company's lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase 1a clinical trial for the treatment of pancreatic cancer and other solid tumors. It is also developing Pan-RAS that is in preclinical stage for the treatment of advanced solid tumors. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California. more
Time Frame | QLGN | Sector | S&P500 |
---|---|---|---|
1-Week Return | -7.95% | 0.31% | -1.26% |
1-Month Return | -7.74% | 0.6% | -4.16% |
3-Month Return | -51.9% | -9.44% | -0.46% |
6-Month Return | -79.05% | -5.15% | 3.58% |
1-Year Return | -83.99% | 0.33% | 22.47% |
3-Year Return | -99.23% | 4.53% | 25.13% |
5-Year Return | -99.83% | 35.98% | 77.7% |
10-Year Return | -100% | 100.72% | 190.12% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 5.56M | 4.31M | 5.65M | 4.98M | 5.20M | [{"date":"2019-12-31","value":98.31,"profit":true},{"date":"2020-12-31","value":76.17,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":88.15,"profit":true},{"date":"2023-12-31","value":92.06,"profit":true}] |
Cost of Revenue | 3.98M | 7.19M | 4.33M | 4.30M | 5.21M | [{"date":"2019-12-31","value":55.36,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":60.29,"profit":true},{"date":"2022-12-31","value":59.88,"profit":true},{"date":"2023-12-31","value":72.49,"profit":true}] |
Gross Profit | 1.58M | (2.88M) | 1.32M | 680.80K | (4.50K) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-182.26,"profit":false},{"date":"2021-12-31","value":83.63,"profit":true},{"date":"2022-12-31","value":43.09,"profit":true},{"date":"2023-12-31","value":-0.28,"profit":false}] |
Gross Margin | 28.43% | (66.87%) | 23.37% | 13.66% | (0.09%) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-235.24,"profit":false},{"date":"2021-12-31","value":82.21,"profit":true},{"date":"2022-12-31","value":48.06,"profit":true},{"date":"2023-12-31","value":-0.3,"profit":false}] |
Operating Expenses | 3.08M | 17.40M | 23.98M | 18.62M | 6.10M | [{"date":"2019-12-31","value":12.85,"profit":true},{"date":"2020-12-31","value":72.55,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":77.65,"profit":true},{"date":"2023-12-31","value":25.42,"profit":true}] |
Operating Income | (1.50M) | (11.30M) | (22.66M) | (17.94M) | (11.30M) | [{"date":"2019-12-31","value":-150320200,"profit":false},{"date":"2020-12-31","value":-1130352200,"profit":false},{"date":"2021-12-31","value":-2266303600,"profit":false},{"date":"2022-12-31","value":-1794239900,"profit":false},{"date":"2023-12-31","value":-1130485700,"profit":false}] |
Total Non-Operating Income/Expense | (280.31K) | (7.95M) | 4.81M | 846.16K | (2.70M) | [{"date":"2019-12-31","value":-5.82,"profit":false},{"date":"2020-12-31","value":-165.05,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":17.58,"profit":true},{"date":"2023-12-31","value":-56.08,"profit":false}] |
Pre-Tax Income | (1.78M) | (20.42M) | (17.89M) | (21.30M) | (12.48M) | [{"date":"2019-12-31","value":-178351200,"profit":false},{"date":"2020-12-31","value":-2041956100,"profit":false},{"date":"2021-12-31","value":-1789171000,"profit":false},{"date":"2022-12-31","value":-2129971700,"profit":false},{"date":"2023-12-31","value":-1247980300,"profit":false}] |
Income Taxes | 4.00K | 619.00 | 5.43K | (265.07K) | (4.79K) | [{"date":"2019-12-31","value":73.71,"profit":true},{"date":"2020-12-31","value":11.41,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-4884.36,"profit":false},{"date":"2023-12-31","value":-88.32,"profit":false}] |
Income After Taxes | (1.79M) | (20.42M) | (17.90M) | (21.03M) | (12.48M) | [{"date":"2019-12-31","value":-178751200,"profit":false},{"date":"2020-12-31","value":-2042018000,"profit":false},{"date":"2021-12-31","value":-1789713700,"profit":false},{"date":"2022-12-31","value":-2103464300,"profit":false},{"date":"2023-12-31","value":-1247501000,"profit":false}] |
Income From Continuous Operations | (1.79M) | (27.53M) | (17.90M) | (21.03M) | (12.48M) | [{"date":"2019-12-31","value":-178751200,"profit":false},{"date":"2020-12-31","value":-2752884000,"profit":false},{"date":"2021-12-31","value":-1789713700,"profit":false},{"date":"2022-12-31","value":-2103464300,"profit":false},{"date":"2023-12-31","value":-1247501000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (1.79M) | (20.42M) | (17.90M) | (21.03M) | (13.42M) | [{"date":"2019-12-31","value":-178751200,"profit":false},{"date":"2020-12-31","value":-2041894200,"profit":false},{"date":"2021-12-31","value":-1789713700,"profit":false},{"date":"2022-12-31","value":-2103464300,"profit":false},{"date":"2023-12-31","value":-1341721200,"profit":false}] |
EPS (Diluted) | (289.50) | 1.07 | (6.10) | (4.10) | (9.47) | [{"date":"2019-12-31","value":-27056.07,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-570.09,"profit":false},{"date":"2022-12-31","value":-383.18,"profit":false},{"date":"2023-12-31","value":-885.51,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
QLGN | |
---|---|
Cash Ratio | 0.09 |
Current Ratio | 0.52 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
QLGN | |
---|---|
ROA (LTM) | -75.07% |
ROE (LTM) | -841.66% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
QLGN | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 1.93 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | -0.93 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
QLGN | |
---|---|
Trailing PE | 0.00 |
Forward PE | NM |
P/S (TTM) | 0.39 |
P/B | 0.41 |
Price/FCF | NM |
EV/R | 0.68 |
EV/Ebitda | NM |
Qualigen Therapeutics Inc (QLGN) share price today is $4.05
Yes, Indians can buy shares of Qualigen Therapeutics Inc (QLGN) on Vested. To buy Qualigen Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in QLGN stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Qualigen Therapeutics Inc (QLGN) via the Vested app. You can start investing in Qualigen Therapeutics Inc (QLGN) with a minimum investment of $1.
You can invest in shares of Qualigen Therapeutics Inc (QLGN) via Vested in three simple steps:
The 52-week high price of Qualigen Therapeutics Inc (QLGN) is $29.43. The 52-week low price of Qualigen Therapeutics Inc (QLGN) is $3.34.
The price-to-earnings (P/E) ratio of Qualigen Therapeutics Inc (QLGN) is 0.0011
The price-to-book (P/B) ratio of Qualigen Therapeutics Inc (QLGN) is 0.41
The dividend yield of Qualigen Therapeutics Inc (QLGN) is 0.00%
The market capitalization of Qualigen Therapeutics Inc (QLGN) is $2.98M
The stock symbol (or ticker) of Qualigen Therapeutics Inc is QLGN